Stigma Surrounding the Use of Medically Assisted Treatment for Opioid Use Disorder

• Published in: Substance use & misuse Vol. 56; no. 10; pp. 1467 - 1475
• Main Authors: Witte, Tricia H., Jaiswal, Jessica, Mumba, Mercy N., Mugoya, George C. T.
• Format: Journal Article
• Language: English
• Published: Philadelphia Taylor & Francis 24.08.2021; Taylor & Francis Ltd
• Subjects: Academic achievement; Agonists; Between-subjects design; Clinical outcomes; discrimination; Drug abuse; Drugs; Efficacy; Heroin; medically assisted treatment; Narcotics; Nicotine; opioid agonist medication; opioid use disorder; Opioids; Pain; Patient satisfaction; Patients; Public opinion; Stigma; Substance abuse treatment; Substance use disorder; Treatment compliance
• ISSN: 1082-6084; 1532-2491; 1532-2491
• DOI: 10.1080/10826084.2021.1936051

This study sought to determine whether certain factors influenced public stigma toward the use of medication to treat opioid use disorders (MOUD). Method: In a series of 3 studies using between-subjects designs, hypothetical MOUD patients matched in age and educational status with the participants were varied in systematic ways to determine whether certain factors influenced stigmatizing views of the patients. Results: Study 1 (n = 142) determined that stigma levels were elevated for hypothetical patients receiving agonist medication for OUD compared to other medications or no medication at all. Study 2 (n = 144) found that hypothetical patients receiving opioid agonist medication for either heroin or pain pills were equally stigmatized and stigmatized more than hypothetical patients on nicotine agonist medication. Study 3 (n = 151) showed that stigmatizing attitudes did not change as a result of enhanced treatment services for hypothetical MOUD patients (i.e. therapy as a supplement to medication). Conclusions/Importance: Results indicate that patients receiving agonist medication for an OUD may be the target of public stigma. Public education on the efficacy of agonist medications for OUD is urgently needed to help reduce such stigma, which may facilitate treatment delivery, treatment adherence, and treatment success.